Global Autoimmune Polyglandular Syndrome Type 1 Market Propelled by Growing Diagnosis and Treatment Rates
The global autoimmune polyglandular syndrome type 1 market comprises products utilized in the diagnosis and treatment of autoimmune polyglandular syndrome type 1 (APS1), commonly known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). APS1 is a rare monogenic disease characterized by the early onset of chronic mucocutaneous candidiasis followed by the development of hypoparathyroidism and adrenal insufficiency. The increasing diagnosis rates owing to growing awareness and identification of genetic mutations causing APS1 is driving the demand for diagnostic products such as genetic and biochemical tests. Moreover, the need for lifelong treatment of signs and symptoms through hormone replacement therapy and antifungal drugs is boosting the growth of the autoimmune polyglandular syndrome type 1 market. The Global Autoimmune Polyglandular Syndrome Type 1 Market is estimated to be valued at US$ 257 Mn in 2024 and is expected to exhibit a CAGR of 3.1% over the forecast period 2024 To 2031.
Key Takeaways
Key players operating in the global autoimmune polyglandular syndrome type 1 market are Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, F. Hoffmann-La Roche Ltd., Zydus Cadila, Lupin, Amneal Pharmaceuticals LLC., Cipla Inc., Aurobindo Pharma, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Allergan, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Abbott, and LEO Pharma A/S.
The rising prevalence of Autoimmune Polyglandular Syndrome Type 1Market Size and growing public awareness about the condition are fueling the demand for diagnosis and treatment. Moreover, ongoing clinical trials evaluating new treatment regimens are also boosting market growth.
The market is witnessing high growth in developing countries due to increasing healthcare expenditures and expansion of private healthcare insurance coverage supporting the treatment costs of rare diseases. Major market players are also focusing on emerging markets through collaborations.
Market Drivers
The global autoimmune polyglandular syndrome type 1 market is primarily driven by the increasing diagnosis rates owing to growing identification of genetic mutations associated with APS1 and expanding research on the disease etiology. Moreover, lack of alternative treatment options have ensured lifelong dependence on maintenance therapies comprising hormone replacement and antifungal drugs, thereby supporting the market growth over the forecast period.
Get more insights on This Topic- Autoimmune Polyglandular Syndrome Type 1Market
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian